Strata Critical Medical (SRTA) Income towards Parent Company (2019 - 2026)

Strata Critical Medical has disclosed Income towards Parent Company across 8 years of filings, most recently posting -$248000.0 for Q1 2026.

• In Q1 2026, Income towards Parent Company rose 86.82% year-over-year to -$248000.0; the TTM figure through Mar 2026 stood at $59.6 million (up 601.28% YoY), while the FY2025 annual figure was $61.4 million, up 650.99% from the prior year.
• Income towards Parent Company climbed to -$248000.0 in Q1 2026, from -$3.4 million in the prior quarter.
• Over the last five years, Income towards Parent Company for SRTA reached as high as $67.1 million in Q3 2025 and fell as low as -$33.9 million in Q4 2023.
• The 5-year median for Income towards Parent Company is -$3.4 million (2025), against an average of -$1.0 million.
• Annual changes were most pronounced in 2022 — Income towards Parent Company sank 918.71% — and 2025, when it jumped 1726.11%.
• A 5-year view of Income towards Parent Company shows it stood at $8.4 million in 2022, then plunged by 503.48% to -$33.9 million in 2023, then soared by 93.04% to -$2.4 million in 2024, then tumbled by 45.79% to -$3.4 million in 2025, then jumped by 92.8% to -$248000.0 in 2026.
• According to Business Quant data, Income towards Parent Company over the past three periods registered -$248000.0, -$3.4 million, and $67.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.